TriSalus Life Sciences, Inc. is classed by the SEC under Surgical & Medical Instruments & Apparatus (industry code 3841), based in Westminster, CO. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $45 million and a loss of $70 million (its filed statements).
Product businessSurgical & Medical Instruments & ApparatusWestminster, COfilings since 20207 of 9 filed, 2 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3841, Surgical & Medical Instruments & Apparatus); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 4.4 out of ten, 7 of 9 metrics filed and 2 estimated: past 3.7 out of ten, present 4.0 out of ten, future 5.5 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 1.5 out of ten. 9 warning events since 2020; the latest 2025-03-28. 15th percentile among 121 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 7.0 out of ten. +53.8% a year over 4 filed years; profitable in 0 of 4. 70th percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 0.2 out of ten. CrossAssetData estimate 0.2/10, confidence 35 of 100 (one part). 2nd percentile among 119 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 4.3 out of ten. Leverage 196%: owes 196¢ per asset dollar. 43rd percentile among 120 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 5.1 out of ten. top 49% of 109 in its family; net margin -86.9%. 51st percentile among 109 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 1.7 out of ten. CrossAssetData estimate 1.7/10, confidence 35 of 100 (one part). 17th percentile among 108 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Room to expand (future): 5.0 out of ten. bottom 50% of 104 in its family for room to expand. 50th percentile among 104 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 5.6 out of ten. top 44% of 105 in its family for growth drivers. 56th percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 6.5 out of ten. top 35% of 88 in its family for expectations against reality. 65th percentile among 88 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-05 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-06 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-06 (on EDGAR). Newest filing: Form 4, 2026-10-07. Filings on record since 2020. Read from EDGAR 2026-10-12.
Who runs it
Szela, Mary T (CEO and President); Patience, David (Chief Financial Officer); Matlin, David J (Chief Financial Officer); Cox, Bryan F. (Chief of Research); Marshak, Richard (Chief Commercial Officer); Stevens, Jennifer (Chief Regulatory Officer); Marshall, Richard Henry (Chief Medical Officer); Devlin, Jodi (Chief of Clinical Operations); Gordon, Gary B. (director); Stansky, Michael P (director); and 3 more. 13 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-07.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.